All In MedTech

Device Trial Radar · NCT07516444

VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)

VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Jul 28, 2026

Primary completion

Jun 2029

Study completion Jun 2036

Sponsor

Lead sponsor
VDyne, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Apr 8, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pivotal trial to evaluate the safety and clinical efficacy of the VDyne TriNova System for the treatment of symptomatic severe or greater tricuspid regurgitation.

Conditions

  • Tricuspid Valve Regurgitation
  • Tricuspid Valve Disease
  • Cardiovascular Diseases (CVD)
  • Heart Valve Diseases
  • Tricuspid Valve Insufficiency
  • Severe Heart Valve Disease
  • Randomized Controlled Trial (RCT)
  • Symptomatic Tricuspid Regurgitation

Interventions

  • Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova SystemDevice

    Subjects will undergo TTVR procedure with VDyne TriNova device and will continue to be managed on Optimal Medical Therapy (OMT).

  • Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE SystemDevice

    Subjects will undergo TTVR procedure with Edwards EVOQUE device and will continue to be managed on Optimal Medical Therapy (OMT).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of major adverse events (MAEs)Time frame: 30 days post-procedure
  2. Composite of all-cause mortality, heart failure hospitalization, or non-elective tricuspid valve reinterventionTime frame: 12 months post-procedure
  3. Change in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)Time frame: 12 months post-procedure

1 more outcomes with a free account

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Banner Health

    Phoenix, Arizona · Recruiting

  • Honor Health

    Scottsdale, Arizona · Recruiting

  • Sutter Health/ California Pacific Medical Center

    San Francisco, California · Recruiting

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.